Background: PIK3CA mutations have been reported to be associated with resistance to therapy in HER2+ breast cancers. This study, therefore, became imperative to determine the expression pattern of this mutant protein together with ER, PR and KI67 in order to serve as a useful predictive tool in the management of HER2 breast cancers.Methods: A total of 53 archived formalin-fixed, paraffin-embedded HER2+ breast cancer tissue blocks from 2015 to 2019 were used for the study in NAUTH Nnewi. The selected blocks were sectioned and stained with haematoxylin and eosin staining techniques. HER2, ER and PR status confirmation as well as PIK3CA and KI67 protein expressions were evaluated using immunohistochemistry (Avidin-biotin complex method). PIK3CA and KI67 expressions in the tissue were scored based on proportion and intensity of immune-labelling using the semi-quantitative method.Result: The mean age of subjects was 47 years and the breast cancers were all invasive ductal carcinoma. Twenty-nine (54.7%) were ER+ while 24 (45.3%) were ER-. Twenty-one (39.6%) were PR+ while 32 (60.4%) were PR-. Twenty-one (39.6%) were PIK3CA negative, 9(35.8%) showed low PIK3CA, while 13(24.5%) showed high PIK3CA. Thirty-four (64.2%) were negative for KI67, 11(20.8%) showed low KI67, while 8(15.5%) showed high KI67. There was weak and moderate positive relationship between ER/PR status and PIK3CA (r=-0.032; p=0.822) and KI67 (r=0.050; p=0.721) respectively. A weak negative correlation between KI67 and PIK3CA (r=-0.118; p=0.401) were observed with 12 (22.4%) of the 13 highly positive PIK3CA cases showing either negative or low for KI67 immunoreactivity while 7(13.2%) of the 8 highly positive KI67 cases showed either negative or low PIK3CA immunoreactivity.Conclusion: This study established a moderate expression of PIK3CA mutant protein. It also pointed out an existing interesting relationship between PIK3CA and KI67, which can be further revealed in future studies.
13 July 2019 in Asian Journal of Pharmaceutical and Clinical Research
Objective: The objective of this study was to evaluate nuclear changes in the buccal epithelial cells of commercial bus drivers using tobacco in Nnewi. Tobacco use constitutes a major risk factor of oral lesions, due to its genotoxic and mutagenic effects on the buccal cavity epithelial cells. Methods: One hundred and twenty-three subjects, consisting of 83 tobacco users (test group) and 40 tobacco and alcohol non-users (control group) were recruited for this cross-sectional study. Buccal smear was obtained from each participant, processed, and stained with the Papanicolaou staining method. Two hundred cells were counted for each stained slide and the percentage of various nuclear changes determined, and the repair index calculated. Comparisons of nuclear changes between and within groups were carried out using the Kruskal–Wallis H-test with p<0.05 considered significant. Results: Micronuclei were the most prevalent nuclear changes (100%) while broken egg nuclei were the least (15.2%). Nuclear changes were most prevalent among snuffers (33.42%). A statistically significant difference (p˂0.05) was observed when the median values of nuclear changes were compared in different study groups and control subjects. Similarly, the prevalence of nuclear changes increased with the age of subjects and the duration of tobacco use, whereas the repair index decreased with increased prevalence. Conclusion: Increased nuclear changes were observed in the buccal epithelial cells of tobacco users, with snuff inhalation slightly impacting more severe effects than cigarette smoking. Buccal smear cytology may constitute an effective screening method for precancerous lesions amongst tobacco users.
Identifying immunocompromised women who are at risk of developing cervical cancer remains a challenge for clinicians. In an effort to identify the role of HIV in cervical carcinogenesis, this study evaluated the levels of normally downregulated oncomirs (miR-21, miR-146a, miR-155, miR-182, and miR-200c) and normally upregulated tumor suppressors (miR-let-7b, miR-125b, miR-143, miR-145, and p53 expression) associated with cervical cancer in the serum of women living with HIV (HIV+) and without HIV (HIV. Method: This case-control study included 173 women; confirmed HIV+ (n = 103) and HIV− (n = 70). Serum levels of miRNAs and p53 were determined using reverse transcriptase PCR. t-test and Pearson’s correlation analyses were carried out on the generated data. Result: A higher level of miR-21 was observed among HIV+ women compared with their HIV− counterpart (p = 0.028), whereas lower levels of miR-125, and p53 gene were observed among HIV+ women compared with HIV− women at p = 0.050 and 0.049, respectively. Significant direct relationships were observed between miR-21 and other oncomirs (p < 0.05) among HIV+ women. Conclusion: This study revealed that HIV contributes to cervical carcinogenesis by modulating circulating levels of miR-21, p53, and miR-125b. It suggests that these biomarkers could be used to identify at high risk for developing cervical cancer.
21 July 2024 in Asian Pacific Journal of Cancer Biology
Background /Introduction: With the increasing incidence of breast cancer, the need for minimally invasive, prompt, cost effective and definitive preoperative assessment of breast lesions using fine needle aspiration cytology (FNAC) may be explored, especially in a developing country. The study was out to classify a broad spectrum of breast lesions diagnosed using FNAC, to determine the prevalence and highlight the efficacy of FNAC in breast lesion diagnosis. Materials and Methods: One hundred and thirty one (131) patients who presented to the Histopathology department of Chukwuemeka Odumegwu Ojukwu University Teaching Hospital, Awka, from 2014 to December 2019 were utilized for this study. Patients’ data and investigation reports were retrieved from the hospital records and laboratory report register. Ethical approval for the study was obtained from the ethics committee of COOUTH, Awka (Ref number: COOUTH/CMAC/ETH.C/VOL 1/FN: 04/0063). Results: The study revealed that seven males (5.4%) and 124 (94.7%) females, with a mean age of 45years presented within the time frame. Benign and malignant lesions accounted for 41.2% (54) and 38.9% (51) respectively, of the total population while inflammatory lesions, ductal carcinoma, Lymphadenitis, chronic abscess and fibro-adenoma accounted for 16.72% (22). Four cases (3.1%) fell into the category of insufficient cells for cytological analysis (C1). Seventy four patients (56.5%) presented with right breast lumps, 48(36.6%) left breast, while 9 (6.9%) presented with lumps on both breasts. Patient with age range of 51-60 years had most frequent malignant cases. Besides, varying clinical presentation of the lumps was observed. Conclusions and Recommendations: Definite diagnosis of malignant breast lesions using FNAC could suggest efficacy, reliability and acceptability of the technique for definitive and early breast lesions diagnosis. Therefore, to enhance early and definitive diagnosis of breast lesions, which is a key factor in management and event free survival rate, FNAC; a less invasive, patients’ acceptable diagnosis technique is advocated.
Prostate cancer remains a major global public health concern, with rising incidence rates worldwide, especially in sub-Saharan Africa. Traditional screening modalities, which rely solely on prostate-specific antigen concentration measurement and digital rectal examination (DRE), have shown poor sensitivity and specificity. Hence, this review critically evaluates emerging multimodal diagnostic strategies, including environmental risk assessment, new cytological and immunohistochemical biomarkers, and genomic profiling, to improve early detection and enable precision therapy for prostate cancer. We examine current information on polycyclic aromatic hydrocarbons as environmental risk indicators, the optimization of post-DRE urine cytology, cytological examination of expressed prostate secretions, and the clinical usefulness of biomarkers such as ERBB2, CDK12, BRCA2, and ATM. Specific attention is paid to the African background, where unique genetic and environmental factors necessitate the development of tailored diagnostic algorithms. This integrative approach provides a theoretical framework for developing comprehensive diagnostic pathways that can enhance early detection rates and deliver individualized treatment in resource-constrained environments. Although the target population of this review is sub-Saharan Africans, the principles and frameworks presented have broader applicability to other low- and middle-income nations facing similar challenges.